SCHEMBL3686360

SCHEMBL3686360

CSCC[C@@H](N)C(=O)NO

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSC P53634 2/20 0.41
RNPEP Q9H4A4 1/20 0.41
ANPEP P15144 2/20 0.40
METAP2 P50579 1/20 0.40
METAP1 P53582 1/20 0.40
HDAC7 Q8WUI4 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
ENPEP Q07075 1/20 0.39
FNTA P49354 2/20 0.37
FNTB P49356 2/20 0.37
PGGT1B P53609 1/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
ARG1 P05089 1/20 0.36
ARG2 P78540 1/20 0.36
MMP2 P08253 1/20 0.35
DPP7 Q9UHL4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1896269 1.00 CTSC (0.41) CTSCRNPEPANPEPMETAP2METAP1
SCHEMBL1920676 1.00 CTSC (0.41) CTSCRNPEPANPEPMETAP2METAP1
Hydrochloric Acid SCHEMBL3458429 0.98 CTSC (0.40) CTSCRNPEPANPEPMETAP2METAP1
Hydrochloric Acid SCHEMBL2253202 0.98 CTSC (0.40) CTSCRNPEPANPEPMETAP2METAP1
Hydrochloric Acid SCHEMBL3458427 0.98 CTSC (0.40) CTSCRNPEPANPEPMETAP2METAP1
SCHEMBL19380208 0.88 NOS3 (0.41) ANPEPMETAP2METAP1HDAC7HDAC8
Norvaline SCHEMBL4543134 0.87 NOS3 (0.42) RNPEPHDAC7HDAC8HDAC6HDAC9
SCHEMBL17746783 0.85 SLC15A1 (0.48) CTSCRNPEPANPEPMETAP2METAP1
SCHEMBL7288155 0.83 CTSC (0.41) CTSCRNPEPANPEPMETAP2METAP1
SCHEMBL6690311 0.83 CTSC (0.41) CTSCRNPEPANPEPMETAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662856-B2 Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine THE UNIVERSITY OF HOUSTON SYSTEM (US) 2010-02-16 US claimed
US-20080249181-A1 Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine KOHN HAROLD 2008-10-09 US claimed
WO-2005020973-A2 COMPOSITIONS HAVING ANTIMYCROBIAL ACTIVITY INCLUDING A HYDROXAMATE OR A HYDROXAMATE AND A HYDROXYLAMINE THE UNIVERSITY OF HOUSTON SYSTEM (US) 2005-03-10 WO claimed
US-7662856-B2 Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine THE UNIVERSITY OF HOUSTON SYSTEM (US) 2010-02-16 US disclosed
US-20080249181-A1 Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine KOHN HAROLD 2008-10-09 US disclosed
WO-2005020973-A2 COMPOSITIONS HAVING ANTIMYCROBIAL ACTIVITY INCLUDING A HYDROXAMATE OR A HYDROXAMATE AND A HYDROXYLAMINE THE UNIVERSITY OF HOUSTON SYSTEM (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249181-A1 Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine CD68, HAAO, HOGA1 CTSC 779/4885RNPEP 2442/4885ANPEP 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.